| dc.contributor.author | Derin, Duygu | |
| dc.contributor.author | Tas, Faruk | |
| dc.contributor.author | Topuz, Erkan | |
| dc.contributor.author | Guney, Nese | |
| dc.contributor.author | Aydiner, Adnan | |
| dc.date.accessioned | 2021-03-05T12:34:18Z | |
| dc.date.available | 2021-03-05T12:34:18Z | |
| dc.date.issued | 2008 | |
| dc.identifier.citation | Tas F., Derin D., Guney N., Aydiner A., Topuz E., "Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, ss.330-334, 2008 | |
| dc.identifier.issn | 1341-9625 | |
| dc.identifier.other | av_add6c44d-a381-48df-aa96-b5c034aa3cc7 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/115982 | |
| dc.identifier.uri | https://doi.org/10.1007/s10147-007-0757-8 | |
| dc.description.abstract | Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients. | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Onkoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer | |
| dc.type | Makale | |
| dc.relation.journal | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | |
| dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
| dc.identifier.volume | 13 | |
| dc.identifier.issue | 4 | |
| dc.identifier.startpage | 330 | |
| dc.identifier.endpage | 334 | |
| dc.contributor.firstauthorID | 188996 | |
